Soleno Therapeutics (NASDAQ:SLNO) Given Sell (D-) Rating at Weiss Ratings

Soleno Therapeutics (NASDAQ:SLNO)‘s stock had its “sell (d-)” rating restated by equities research analysts at Weiss Ratings in a report released on Wednesday,Weiss Ratings reports.

SLNO has been the topic of a number of other reports. Guggenheim reissued a “buy” rating and set a $106.00 target price on shares of Soleno Therapeutics in a report on Wednesday, August 27th. HC Wainwright reissued a “buy” rating and set a $110.00 target price (up from $100.00) on shares of Soleno Therapeutics in a report on Monday, August 18th. Wall Street Zen raised Soleno Therapeutics from a “sell” rating to a “hold” rating in a report on Saturday, July 26th. Cowen reissued a “buy” rating on shares of Soleno Therapeutics in a report on Thursday, August 7th. Finally, Lifesci Capital raised Soleno Therapeutics to a “strong-buy” rating in a report on Wednesday, September 10th. One research analyst has rated the stock with a Strong Buy rating, twelve have assigned a Buy rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, Soleno Therapeutics presently has a consensus rating of “Moderate Buy” and an average price target of $115.92.

Soleno Therapeutics Stock Up 1.0%

NASDAQ:SLNO opened at $62.74 on Wednesday. The firm has a market capitalization of $3.33 billion, a price-to-earnings ratio of -15.15 and a beta of -2.75. Soleno Therapeutics has a twelve month low of $41.50 and a twelve month high of $90.32. The stock’s 50 day moving average price is $67.62 and its two-hundred day moving average price is $73.17. The company has a quick ratio of 15.01, a current ratio of 15.13 and a debt-to-equity ratio of 0.21.

Soleno Therapeutics (NASDAQ:SLNO) last posted its quarterly earnings results on Wednesday, August 6th. The company reported ($0.09) earnings per share for the quarter, topping the consensus estimate of ($0.53) by $0.44. The company had revenue of $32.66 million for the quarter, compared to analyst estimates of $3.91 million. Equities research analysts expect that Soleno Therapeutics will post -3.72 earnings per share for the current fiscal year.

Institutional Trading of Soleno Therapeutics

Institutional investors have recently modified their holdings of the stock. Raymond James Financial Inc. bought a new stake in shares of Soleno Therapeutics during the 2nd quarter valued at $25,000. Nisa Investment Advisors LLC lifted its position in shares of Soleno Therapeutics by 287.8% during the 2nd quarter. Nisa Investment Advisors LLC now owns 539 shares of the company’s stock valued at $45,000 after acquiring an additional 400 shares during the period. AlphaQuest LLC lifted its position in shares of Soleno Therapeutics by 37.5% during the 1st quarter. AlphaQuest LLC now owns 983 shares of the company’s stock valued at $70,000 after acquiring an additional 268 shares during the period. Osaic Holdings Inc. lifted its position in shares of Soleno Therapeutics by 97.7% during the 2nd quarter. Osaic Holdings Inc. now owns 856 shares of the company’s stock valued at $72,000 after acquiring an additional 423 shares during the period. Finally, KBC Group NV bought a new stake in shares of Soleno Therapeutics during the 2nd quarter valued at $77,000. 97.42% of the stock is currently owned by institutional investors.

About Soleno Therapeutics

Soleno Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead candidate is Diazoxide Choline Extended-Release tablets, a once-daily oral tablet, which is in Phase III clinical trials for the treatment of Prader-Willi Syndrome.